Skip to main content
. Author manuscript; available in PMC: 2020 Sep 20.
Published in final edited form as: Curr Cancer Drug Targets. 2020;20(4):253–270. doi: 10.2174/1568009619666191202101330

Fig. 2.

Fig. 2.

Clinical trial overview of Hsp90 inhibitors – 18 Hsp90 inhibitors have entered the clinical pipeline totaling over 170 trials. A) There are currently 7 inhibitors in active or recruiting trials (green or orange, respectively). B) The majority of inhibitors have not progressed past Phase I. Note: active trials testing TAS-116 are in Japan. *Original figure created by authors